In an effort to crack the code of hard-to-treat solid tumors, biopharma has tried numerous pathways to effectively target those masses without damaging healthy tissues. Philly’s Carisma Therapeutics thinks it has a winner with its macrophage cell-based “CAR-M” candidates, and now it’s taking a new flush of investor cash to try one in the clinic.